Application of lactobacillus rhamnosus in preparation of product for preventing and treating systemic lupus erythematosus

By using the products prepared by C. rhamnosus LC-STH-13, the TLR9/NF-κB pathway inhibits renal inflammation and improves intestinal health, the problem of poor treatment of systemic lupus erythematosus in the prior art was solved, and the problem of poor treatment of systemic lupus erythematosus in the prior art was achieved. Significant symptom relief and application prospects.

CN119033829AInactive Publication Date: 2024-11-29HARBIN MEIHUA BIOLOGICAL TECH JOINT CO LTD

Patent Information

Application Number
CN202411556055.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-11-04
Publication Date
2024-11-29
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

In the prior art, there are fewer therapeutic effects on systemic lupus erythematosus, and there are fewer studies on C. rhamnosus.

Method used

Using rhamnosaccharin LC-STH-13 as the main ingredient, different doses of products were prepared by gavage administration (1×10^3-1×10^14 CFU/mL or 1×10^3-1 ×10^14 CFU/g), including live bacteria, fermentation broth and lyophilized powder, combined with pharmaceutically acceptable carriers, makes various dosage forms for the treatment of systemic lupus erythematosus.

Benefits of technology

The TLR9/NF-κB pathway inhibits renal inflammation, improves intestinal microbial dysregulation, reduces colon inflammation and intestinal permeability, significantly alleviates the symptoms of systemic lupus erythematosus, and has broad application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119033829A_ABST
    Figure CN119033829A_ABST
Patent Text Reader

Abstract

The invention discloses application of lactobacillus rhamnosus in preparation of a product for preventing and treating systemic lupus erythematosus, and relates to the technical field of microorganisms. The invention provides application of lactobacillus rhamnosus in preparation of a product for treating autoimmune diseases. The preservation number of the lactobacillus rhamnosus is CGMCC (China General Microbiological Culture Collection Center) No.3994. The invention further provides a preparation method of the lactobacillus rhamnosus. Research finds that the lactobacillus rhamnosus can relieve related symptoms of systemic lupus erythematosus and inhibit kidney inflammation through a TLR9 / NF-kappa B pathway, and the lactobacillus rhamnosus can improve intestinal microbial disorder, relieve colitis and intestinal permeability and has wide application prospects in preparation of products for improving systemic lupus erythematosus.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The invention relates to the technical field of microorganisms, and in particular to application of Lactobacillus rhamnosus in preparing a product for preventing and treating systemic lupus erythematosus. Background Art

[0002] Systemic lupus erythematosus (SLE) is a complex chronic autoimmune disease that can be accompanied by varying degrees of damage to multiple systems throughout the body. Severe SLE often causes failure of multiple important organs such as the heart, lungs, and kidneys, and is one of the common diseases in critical care medicine. The pathogenesis of SLE is very complex. Studies have shown that the activation of the immune system in SLE is characterized by excessive response of B cells and T cells and loss of immune tolerance to self-antigens. When the immune system cannot effectively distinguish between self and foreign antigens, it will cause the body's immune system to become dysregulated, making cells that should be considered harmless become potentially threatening. This disorder may lead to the transformation of inflammatory autoantigen-specific T cells and B cells, thereby causing autoantibody reactions and causing autoimmune reactions to one's own tissue cells and organs.

[0003] The onset of SLE is associated with some genetic risk factors, such as certain HLA haplotypes, certain complement genes, and other genes related to the immune system. At the same time, DNA hypomethylation and reactivation of inactive X chromosomes have also been identified as two epigenetic markers of SLE. In terms of environmental factors, ultraviolet radiation, smoking, drugs, and other factors, such as respiratory exposure to crystalline silica dust or air pollution, exposure to chemicals, organic pollutants or heavy metals, vaccination, infection, drinking, etc. are also inducing factors of SLE.

[0004] Probiotics refer to microorganisms with strong enough activity, sufficient quantity and clear composition. After being ingested by the host, they can successfully colonize in the body, maintain normal flora structure in the body, and produce any health-promoting effects. It can improve the intestinal health of animals through non-immune (improving intestinal microecological balance and intestinal structure) and immune regulation pathways (enhancing intestinal immunity and systemic immune system, reducing inflammatory response) to promote animal growth and development, and achieve the purpose of preventing and treating diseases, such as no toxic side effects and no harmful residues. Lactobacillus rhamnosus ) is a widely used probiotic, mostly found in the intestines of humans and animals. Lactobacillus rhamnosus has biological characteristics such as acid resistance, bile salt resistance, and resistance to multiple antibiotics. It can colonize in the human intestine, is safe for oral administration, and can reproduce in the intestine after oral administration. It has attracted much attention because of its effects on improving the intestinal health of the host, maintaining the normal balance of intestinal flora, relieving inflammation, and immune regulation.

[0005] In the prior art, there are few studies on the therapeutic effect of Lactobacillus rhamnosus on systemic lupus erythematosus, and it is very necessary to provide a probiotic that can effectively treat systemic lupus erythematosus. Summary of the invention

[0006] The purpose of the present invention is to provide application of Lactobacillus rhamnosus LC-STH-13 in preparing products for preventing and treating systemic lupus erythematosus.

[0007] To achieve the above-mentioned object of the invention, the technical solution of the present invention is as follows: In one aspect, the present invention provides the use of Lactobacillus rhamnosus in preparing a product for treating autoimmune diseases, wherein the Lactobacillus rhamnosus has a deposit number of CGMCC No. 3994.

[0008] Specifically, the autoimmune disease is systemic lupus erythematosus.

[0009] Specifically, the product is a medicine.

[0010] Specifically, the viable count of Lactobacillus rhamnosus in the product is 1×10 3 -1×10 14 CFU / mL or 1×10 3 -1×10 14 CFU / g.

[0011] For example, 1×10 3 CFU / mL (CFU / g), 1×10 4 CFU / mL (CFU / g), 1×10 5 CFU / mL (CFU / g), 1×10 6 CFU / mL (CFU / g), 1×10 7 CFU / mL (CFU / g), 1×10 8 CFU / mL (CFU / g), 1×10 9 CFU / mL (CFU / g), 1×10 10 CFU / mL (CFU / g), 1×10 11 CFU / mL (CFU / g), 1×10 12 CFU / mL (CFU / g), 1×10 13 CFU / mL (CFU / g), 1×10 14 CFU / mL (CFU / g), etc. Other point values ​​within this numerical range can be selected.

[0012] Furthermore, the viable count of Lactobacillus rhamnosus in the product is 1×10 8 -1×10 10CFU / mL or 1×10 8 -1×10 10 CFU / g.

[0013] Furthermore, the viable count of Lactobacillus rhamnosus in the product is 1×10 10 CFU / mL or 1×10 10 CFU / g.

[0014] Specifically, the Lactobacillus rhamnosus includes fermentation liquid of Lactobacillus rhamnosus, live Lactobacillus rhamnosus bacteria, and freeze-dried powder of Lactobacillus rhamnosus.

[0015] Furthermore, the fermentation liquid of Lactobacillus rhamnosus refers to the liquid obtained after the bacteria are inoculated into the culture medium and cultured.

[0016] Furthermore, the live bacteria, also called active flora, can colonize and multiply in the intestine, which is beneficial to increase the number of beneficial bacteria.

[0017] Furthermore, the freeze-dried powder refers to the powder obtained by freeze-drying the strains.

[0018] Preferably, the drug further comprises a pharmaceutically acceptable carrier.

[0019] Further preferably, the pharmaceutically acceptable carrier is selected from one or more of an excipient, a stabilizer, a diluent, a binder, a preservative, and a lubricant.

[0020] Specifically, the excipient is selected from at least one of microcrystalline cellulose, lactose, pregelatinized starch, cyclodextrin, carboxymethyl cellulose and mannitol.

[0021] Specifically, the stabilizer is selected from at least one of agar, alginic acid, cellulose ether, and carboxymethyl chitosan.

[0022] Specifically, the diluent is selected from at least one of erythritol, mannitol, sorbitol, xylitol, lactose, sucrose, corn starch, potato starch, calcium phosphate, calcium citrate, and crystalline cellulose.

[0023] Specifically, the binder is selected from at least one of ethanol, starch slurry, syrup, hydroxypropyl methylcellulose, sodium carboxymethyl cellulose, sodium alginate, and polyvinyl pyrrolidone.

[0024] Specifically, the preservative is selected from at least one of methylparaben, propylparaben, methylparaben, ethylparaben, propylparaben, chlorobutanol, thimerosal, mercuric cyanide, phenoxyethanol, chlorhexidine, benzoic acid, sodium benzoate, chlorocresol, benzalkonium bromide, benzalkonium chloride, and ethylparaben.

[0025] Specifically, the lubricant is selected from at least one of magnesium stearate, stearic acid, sodium chloride, sodium oleate, sodium lauryl sulfate, and poloxamer.

[0026] Specifically, the dosage form of the drug is drops, mixtures, tinctures, injections, tablets, powders, oral liquids, capsules, granules, ointments, suspensions, powders, emulsions, solutions, pellets, pills, buccal tablets, lyophilized powder injections, gels, suppositories or aerosols.

[0027] In another aspect, the present invention provides a drug for treating autoimmune diseases, wherein the drug contains Lactobacillus rhamnosus, and the deposit number of the Lactobacillus rhamnosus is CGMCC No. 3994.

[0028] Specifically, the autoimmune disease is systemic lupus erythematosus.

[0029] Specifically, the medicine may further include a pharmaceutically acceptable carrier.

[0030] Furthermore, the pharmaceutically acceptable carrier is selected from one or more of an excipient, a stabilizer, a diluent, a binder, a preservative, and a lubricant.

[0031] Specifically, the dosage form of the drug is drops, mixtures, tinctures, injections, tablets, powders, oral liquids, capsules, granules, ointments, suspensions, powders, emulsions, solutions, pellets, pills, buccal tablets, lyophilized powder injections, gels, suppositories or aerosols.

[0032] Specifically, the viable count of Lactobacillus rhamnosus in the drug is 1×10 3 -1×10 14 CFU / mL or 1×10 3 -1×10 14 CFU / g.

[0033] Furthermore, the viable count of Lactobacillus rhamnosus in the drug is 1×10 8 -1×10 10 CFU / mL or 1×10 8 -1×10 10 CFU / g.

[0034] Furthermore, the viable count of Lactobacillus rhamnosus in the drug is 1×10 10 CFU / mL or 1×10 10 CFU / g.

[0035] In another aspect, the present invention provides the use of Lactobacillus rhamnosus in preparing a product for treating nephritis, wherein the Lactobacillus rhamnosus has a deposit number of CGMCC No. 3994.

[0036] Specifically, the nephritis is lupus nephritis.

[0037] Specifically, the product is a medicine.

[0038] Specifically, the viable count of Lactobacillus rhamnosus in the product is 1×10 3 -1×10 14 CFU / mL or 1×10 3 -1×10 14 CFU / g.

[0039] Furthermore, the viable count of Lactobacillus rhamnosus in the product is 1×10 8 -1×10 10 CFU / mL or 1×10 8 -1×10 10 CFU / g.

[0040] Furthermore, the viable count of Lactobacillus rhamnosus in the product is 1×10 10 CFU / mL or 1×10 10 CFU / g.

[0041] Specifically, the Lactobacillus rhamnosus includes fermentation liquid of Lactobacillus rhamnosus, live Lactobacillus rhamnosus bacteria, and freeze-dried powder of Lactobacillus rhamnosus.

[0042] The beneficial effects of the present invention are as follows: the present invention provides an application of Lactobacillus rhamnosus LC-STH-13 in the preparation of a product for treating systemic lupus erythematosus. Experimental data implemented according to the present invention show that Lactobacillus rhamnosus LC-STH-13 is effective in relieving systemic lupus erythematosus by intragastric administration. Lactobacillus rhamnosus can relieve the relevant symptoms of systemic lupus erythematosus and inhibit kidney inflammation through the TLR9 / NF-κB pathway. The bacteria can improve intestinal microbial imbalance, reduce colon inflammation and intestinal permeability, and has broad application prospects in the preparation of products for improving systemic lupus erythematosus. BRIEF DESCRIPTION OF THE DRAWINGS

[0043] Figure 1Evaluation of the probiotic properties of Lactobacillus rhamnosus LC-STH-13; in the figure, (A) is the growth curve of LC-STH-13; (BC) is the evaluation of the acid resistance of LC-STH-13; (D) is the evaluation of the bile resistance of LC-STH-13; (E) is the evaluation of the antioxidant properties of LC-STH-13; (F) is the growth inhibition of LC-STH-13 bacterial solution on intestinal pathogens; (G) is the representative result of the evaluation of the adhesion of LC-STH-13 to HT-29 cells; (H) is a representative picture of the hemolysis test results of LC-STH-13; (I) is a representative picture of the drug sensitivity test results of LC-STH-13.

[0044] Figure 2 Lactobacillus rhamnosus LC-STH-13 alleviated the lupus phenotype of MRL / lpr mice; MRL / lpr female mice were intragastrically administered with normal saline (M), prednisolone (Pred), 10 7 or 10 9 CFU LC-STH-13 (L-LC or H-LC) were added daily from 8 to 16 weeks as indicated in C57BL / 6 female mice treated with saline as controls.

[0045] Figure 3 Lactobacillus rhamnosus LC-STH-13 alleviates the lupus phenotype of MRL / lpr mice; (A) shows the weight changes of experimental mice over time; (BC) show the levels of antinuclear antibodies (ANA) and anti-double-stranded DNA (ds-DNA) antibodies in the serum of 16-week-old mice.

[0046] Figure 4 Lactobacillus rhamnosus LC-STH-13 alleviates the lupus phenotype of MRL / lpr mice; (A) is a representative picture of mouse spleen; (B) is the spleen index of mice.

[0047] Figure 5 Representative results of flow cytometry detection of Th17 cells in mouse spleen.

[0048] Figure 6 Representative results of flow cytometry detection of Treg cells in mouse spleen.

[0049] Figure 7 is the relative percentage of Th17 and Treg cells to CD4 cells in the spleen of mice.

[0050] Figure 8 (A) and (B) show the improving effect of Lactobacillus rhamnosus LC-STH-13 on renal injury in MRL / lpr mice; (B) show the levels of Scr and BUN in serum detected by blood biochemical instrument.

[0051] Fig. 9 Representative images of HE staining of mouse kidney.

[0052] Fig.10 Representative images of IgG immunofluorescence in mouse kidney.

[0053] Fig.11 Representative images of C3 immunofluorescence in mouse kidneys.

[0054] Fig.12 Lactobacillus rhamnosus LC-STH-13 reduces renal immune complex deposition and inflammation in MRL / lpr mice; (A) Western-blotting was used to detect the expression levels of complement C3 and complement C5 in the kidney; (BC) ImageJ was used to quantitatively analyze the WB results of complement C3 and complement C5, respectively.

[0055] Fig.13 Lactobacillus rhamnosus LC-STH-13 reduces renal immune complex deposition and inflammation in MRL / lpr mice; (AC) qPCR detection of the transcription levels of IFN-α, IL-1 and IL-6 in the kidneys.

[0056] Fig.14 Lactobacillus rhamnosus LC-STH-13 reduces renal immune complex deposition and inflammation in MRL / lpr mice; (A) Western-blotting was used to detect the expression levels of TLR9, Myd88, p-NF-κB, and NF-κB in the kidney; (BC) ImageJ was used to quantitatively analyze the WB results of TLR9 and p-NF-κB, respectively.

[0057] Fig.15 Lactobacillus rhamnosus LC-STH-13 alleviates intestinal microbial disorders in MRL / lpr mice; (AC) α-diversity analysis of mouse intestinal flora, including Chao 1 index, Observed_species, and Faith_pd index.

[0058] Fig.16 Lactobacillus rhamnosus LC-STH-13 alleviates intestinal microbial disorders in MRL / lpr mice; (A) is a Venn diagram representing the number of unique OTUs among each group; (B) is a PCoA analysis representing the β-diversity of intestinal flora.

[0059] Fig.17 Lactobacillus rhamnosus LC-STH-13 alleviates intestinal microbial disorders in MRL / lpr mice; (A) is species composition analysis (phylum level); (BC) are the abundances of Bacteroidetes and Firmicutes, respectively.

[0060] Fig.18 Lactobacillus rhamnosus LC-STH-13 alleviates intestinal microbial disorders in MRL / lpr mice; (A) species composition analysis (genus level); (B) abundance of Lactobacillus genus.

[0061] Fig.19 Lactobacillus rhamnosus LC-STH-13 reduces intestinal barrier damage and inflammation levels in MRL / lpr mice; Figure 2 shows the results of HE staining of colon tissue.

[0062] Fig. 20 Lactobacillus rhamnosus LC-STH-13 alleviates intestinal barrier damage and inflammation levels in MRL / lpr mice; (A) Western-blotting was used to detect the expression levels of ZO-1, Occludin, and Claudin-1 proteins in the colon; (BD) ImageJ was used to quantitatively analyze the WB results of ZO-1, Occludin, and Claudin-1, respectively.

[0063] Fig.21 Lactobacillus rhamnosus LC-STH-13 alleviates intestinal barrier damage and inflammation levels in MRL / lpr mice; (AC) qPCR detection of TNF-α, IL-1 and IL-6 transcription levels in the colon; (D) Western-blotting detection of TLR4, MyD88, p-NF-κB, NF-κB, p-IκB, IκB protein expression levels in the colon.

[0064] Fig. 22 Lactobacillus rhamnosus LC-STH-13 alleviates intestinal barrier damage and inflammation levels in MRL / lpr mice; (AD) Quantitative analysis of WB results of TLR4, MyD88, p-NF-κB, and p-IκB using ImageJ, respectively.

[0065] In the figure above, C, control group; M, systemic lupus erythematosus model group; Pred, prednisolone group; L-LC, low dose (10 7 CFU) LC-STH-13 group; H-LC, high dose (10 9 CFU) LC-STH-13 group, * p <0.05,** p <0.01,*** p <0.001. DETAILED DESCRIPTION

[0066] In order to make the technical means, creative features, purpose and efficacy of the present invention easy to understand, the present invention is further explained in conjunction with specific embodiments below, but the following embodiments are only preferred embodiments of the present invention, not all. Based on the embodiments in the implementation mode, other embodiments obtained by those skilled in the art without creative work all belong to the protection scope of the present invention. In the following embodiments, unless otherwise specified, the operating methods used are conventional operating methods, the equipment used are conventional equipment, and the equipment materials used in each embodiment are the same.

[0067] The Lactobacillus rhamnosus LC-STH-13 described in the present invention has a preservation number of CGMCC No. 3994, which has been disclosed in patent CN103031263A.

[0068] Example 1 1 Experimental animals and groups 1.1 Experimental animals 40 MRL / lpr female mice (SPF grade, 6-8 weeks old, weighing 18-22 g) were purchased, and 10 C57BL / 6 mice were selected as the normal control group. The experiment was started after at least one week of laboratory adaptation.

[0069] 1.2 Experimental Grouping (1) Normal control group: C57BL / 6 mice (N=10); (2) Model group: MRL / lpr mice (N=10); (3) Positive control group: daily intragastric administration of prednisolone (5 mg / kg) 100 μL (N=10); (4) Low-dose Lactobacillus rhamnosus treatment group: bacterial liquid concentration was 1×10 8 CFU / mL, 100 μL was administered orally daily, i.e. 1×10 7 bacteria (N=10); (5) High-dose Lactobacillus rhamnosus treatment group: bacterial liquid concentration was 1×10 10 CFU / mL, 100μL was administered orally daily, i.e. 1×10 9 bacteria (N=10).

[0070] 2 Experimental methods 2.1 In vitro culture 2.1.1 Cultivation of Lactobacillus rhamnosus (1) Preparation of culture medium MRS liquid culture medium (purchased from Haibo Biotechnology, catalog number HB0384-1): prepare an appropriate amount of culture medium according to the required plates and the culture medium configuration method.

[0071] MRS solid culture medium: Add 2% agar to the liquid culture medium, shake well, and seal.

[0072] (2) Sterilization of culture medium and equipment Place the MRS medium in an autoclave at 115°C for 20 min.

[0073] Pipette tips, centrifuge tubes, culture dishes, etc. were sterilized by high pressure sterilization at 121°C for 20 min.

[0074] (3) Sterilization of sterile clean bench Open the sterile clean bench and sterilize with UV light for 15 minutes. After sterilization, turn on the lighting and switch and adjust the wind speed to the middle level.

[0075] (4) Cultivation of bacterial strains In a clean bench (disinfect your hands with 75% alcohol before use), transfer the bacterial solution to MRS solid culture medium, spread it evenly with a glass rod, and culture it anaerobically at 37°C for 24-48 h.

[0076] (5) Expansion of bacterial strains Pick a single colony from the solid culture medium and inoculate it into the liquid culture medium (5 mL), and culture it in a constant temperature shaker at 37°C for 24 h.

[0077] (6) Continued expansion of bacterial culture Pipette 100 μL of bacterial solution from the above 1 mL into a glass tube containing 5 mL of culture medium and continue activation for 6 h.

[0078] (7) Measure OD value After activation, the OD value was measured. Generally, when OD 600 = 1.0, the corresponding bacterial concentration was 1 × 10 9 CFU / mL, and then dilute the bacterial solution to the required concentration.

[0079] 2.2 Acid resistance test PBS buffer, adjust pH to 2, 3, 4, 5, 7 respectively. Prepare MRS solid culture medium. Sterilize and pour the plate. Seal the plate with sealing film and put it in a 4℃ refrigerator. Take 100 μL of Lactobacillus rhamnosus bacterial liquid and add 5 mL of MRS liquid culture medium. Culture in 37℃ anaerobic incubator overnight.

[0080] Take 100 μL of Lactobacillus rhamnosus bacterial solution and dilute it by 10 steps with PBS buffer. 1 , 10 3 , 10 5Multiple times (take 100 μL and add it to 900 μL PBS buffer, then take 10 μL and add it to 990 μL PBS, then take 10 μL and add it to 990 μL PBS) 10 EP tubes for each gradient. Centrifuge at 2500 rpm for 4 min and discard the supernatant. Add PBS buffer with pH 2, 3, 4, 5, 7, place it anaerobically for 4 h, mix well, take 10 μL and spread it on the plate, and culture it in an anaerobic incubator at 37℃ overnight. Count the viable bacteria.

[0081] 2.3 Bile salt tolerance test (1) MRS liquid culture medium with bile salts. No. 1 (without bile salts), No. 2 (with 0.1% bile salts), No. 3 (with 0.2% bile salts), No. 4 (with 0.3% bile salts), and sterilized MRS solid culture medium.

[0082] (2) After sterilization, pour the plates, seal them with sealing film and place them in a 4℃ refrigerator.

[0083] (3) Take 100 μL of Lactobacillus rhamnosus bacterial culture and add it to 5 mL of MRS liquid culture medium with different bile salt concentrations. Culture in a 37°C incubator overnight.

[0084] (4) In the morning, take out the cultured bacterial solution, mix it well, and apply 10 μL on the solid culture medium. Incubate it in a 37℃ incubator for 24 h and count the viable bacteria.

[0085] 2.4 Adhesion test (1) Take out 200 μL of Lactobacillus rhamnosus bacterial culture and add it to 5 mL of MRS liquid culture medium and culture it in a 37°C incubator. When the OD value reaches 0.6, terminate the culture (approximately 4 h) and keep it for later use.

[0086] (2) Wash the six-well cell culture plate once with sterile PBS buffer and place a sterilized coverslip. Subculture HT29 cells and culture on the cell culture plate until the cell count reaches 30%. Inoculate Lactobacillus rhamnosus with an OD value of 0.6 and culture in a cell culture incubator at 37°C. (3) After 2 h of incubation, the six-well tissue cell culture plate was removed, the culture medium was aspirated, and the cells were repeatedly washed five times with PBS buffer, fixed with methanol, Gram-stained, and observed under an oil immersion microscope.

[0087] Gram stain: 1) Smear: Make smears of different cultured bacteria (note that the smears must not be too thick), dry and fix. Use methanol for fixation.

[0088] 2) Primary staining: add 1 drop of ammonium oxalate crystal violet, stain for about 1 min, and wash with water.

[0089] 3) Mordanting: Add iodine solution and cover for about 1 min, then wash with water.

[0090] 4) Decolorization: Shake off the water on the slide, and place it against a white background. Wash it with 95% alcohol until the alcohol just stops turning purple, about 20-30 seconds, and immediately rinse it with water.

[0091] 5) Re-staining: Dye with safranin for 1 min and wash with water.

[0092] 6) Microscopic examination: After drying, observe under an oil microscope. Gram-negative bacteria appear red, and Gram-positive bacteria appear purple. The Gram staining reaction of dispersed bacteria shall prevail.

[0093] 2.5 Antagonistic pathogenic bacteria experiment Take 1 mL of Lactobacillus rhamnosus bacterial solution, centrifuge 1 mL at 2500 rpm for 4 min, and take the supernatant. Dilute 100 times with PBS (take 100 μL of supernatant / bacterial solution into 900 μL of PBS, and then take 100 μL from it into a new 900 μL of PBS). Take 20 μL of 8 pathogenic bacteria (Staphylococcus aureus, Shigella flexneri, Shigella 301, Salmonella enteritidis, Escherichia coli O157, Salmonella typhimurium, Candida albicans, and hemolytic Streptococcus) and spread them on the LB solid culture medium plate, put an Oxford cup on it, and draw 250 μL of Lactobacillus rhamnosus bacterial solution and its culture medium into the Oxford cup, and culture it in a 37°C incubator. Observe the size of the inhibition zone every two hours, and measure the diameter after 8 hours.

[0094] 2.6 Antioxidant test (1) Solution preparation: MRS liquid culture medium, deionized water; 0.2 mmol / L DPPH methanol solution; 2 mmol / L ferrous sulfate solution, 6 mmol / L hydrogen peroxide solution, 6 mmol / L salicylic acid solution; 150 mmol / L Tris-HCl solution at pH 8.0, 1.2 mmol / L pyrogallol solution; 0.4% ferrous sulfate solution, 1% Vc, 0.2 mol / L sodium hydroxide solution, 10% trichloroacetic acid solution, 0.1% o-phenanthroline solution; pH 6.6 phosphate buffer, 1% potassium ferrocyanide solution, 0.1% ferric chloride solution.

[0095] (2) Activation: Take 100 μL of Lactobacillus rhamnosus bacterial culture and add it to a glass reagent tube containing 5 mL of MRS medium. Incubate the culture in a 37°C incubator overnight. The next day, centrifuge and take the supernatant.

[0096] (3) Determination of DPPH free radical scavenging ability Take 2 mL of the supernatant and add it to a glass test tube. Then add 2 mL of the prepared DPPH methanol solution. Incubate at room temperature in the dark for 30 min and centrifuge to collect the supernatant. Add 2 mL of deionized water and 2 mL of DPPH methanol solution to another glass test tube as a control. Measure the OD value at 517 nm. Record the data of the control group and the experimental group. DPPH free radical scavenging rate = [1-A517 (sample) / A517 (blank)] × 100%.

[0097] (4) Hydroxyl radical scavenging ability Take 1 mL of bacterial supernatant and add it to a glass test tube. Add 1 mL of ferrous sulfate solution, 1 mL of hydrogen peroxide solution, and 1 mL of salicylic acid solution. Let it stand for 30 min. Add the above solution to another glass tube and add 1 mL of deionized water. After 30 min, measure the absorbance at 510 nm. Record the data of the control group and the experimental group. Hydroxyl radical scavenging rate = [1-A510(sample) / A510(blank)] × 100%.

[0098] (5) Superoxide free radical scavenging ability Take 0.5 mL of bacterial supernatant and add it to glass test tube No. 1, add 2 mL of Tris-HCl solution and 1 mL of pyrogallol solution, and react at room temperature for 30 min. Add 0.5 mL of deionized water, 1 mL of pyrogallol and 2 mL of 2 mLTris-HCl solution to test tube No. 2, add 1.5 mL of deionized water and 2 mL of Tris-HCl solution to test tube No. 3, and add 1 mL of deionized water, 0.5 mL of bacterial supernatant and 2 mL of Tris-HCl solution to test tube No. 4.

[0099] Superoxide radical scavenging rate = [1-(A11-A10) / (A01-A00)] × 100%.

[0100] A00: without sample and pyrogallol (3); A01: without sample and containing pyrogallol (2); A10: Contains the sample but not pyrogallol (4); A11: Contains the sample and pyrogallol (1).

[0101] (6) Chelating ability of ferrous ions Take 0.5 mL of bacterial supernatant and add it to a glass tube. Add 0.1 mL of ferrous sulfate solution and mix well. Then add 0.1 mL of Vc and 1 mL of sodium hydroxide solution. React in a 37°C oven for 20 min. Then add trichloroacetic acid and centrifuge to remove protein at 6000 rpm, 10 min, and 4°C. Take 0.4 mL of supernatant and add 4 mL of o-phenanthroline. Add 0.5 mL of water to another test tube, and do the same. React at room temperature for 10 min and measure the absorbance at 536 nm. Record the data of the control group and the experimental group.

[0102] Fe 2+ The chelating capacity = (A blank - A sample / A blank) × 100%.

[0103] (7) Determination of total reducing power Take 1 mL of bacterial supernatant, add 1 mL of phosphate buffer and 1 mL of potassium ferricyanide, mix well, keep warm at 50℃ for 2 min, add 1 mL of trichloroacetic acid, shake and mix well, take 1 mL of the mixture, add 4 mL of deionized water and 0.4 mL of ferric chloride solution, and let stand for 10 min. Add 1 mL of deionized water to another test tube, and the other reagents and treatments are the same. After standing, measure the absorbance and use deionized water as a blank. Measure the absorbance at 700 nm and record the data of the control group and the experimental group.

[0104] 2.7 Hemolysis test Take the twice activated Lactobacillus rhamnosus bacterial suspension, centrifuge at 4000 rpm / min for 3 min, take the precipitate, and resuspend it in sterile PBS. Spot 10 μL of the bacterial suspension on BHI agar plates containing 10% defibrinated sheep blood, place them in a 37°C incubator for 24 h, and observe whether hemolysis occurs.

[0105] 2.8 Drug sensitivity test Take 30 μL of the twice activated Lactobacillus rhamnosus bacterial solution and spread it on the MRS agar plate, then stick the drug-sensitive paper on the surface of the agar plate. After incubating at 37°C for 16-18 h, measure and record the diameter of the inhibition zone.

[0106] 3 Experimental methods 3.1 Animal organ observation Samples collected: urine, blood, kidney, intestine, brain (the spleen and lymph nodes may appear swollen and can be photographed).

[0107] 3.1.1 Blood Serum urea nitrogen (BUN) and serum creatinine (Scr) were detected using 330 Mindray automatic biochemical analyzer.

[0108] 3.1.2 Spleen Detection indicators: Th17 cells, Treg cells.

[0109] Flow cytometry detection of Th17 cells and Treg cells in the spleen: (1) Lift the peritoneum from the lower side of the spleen, cut it open and flip it up to expose the spleen. Lift the spleen with forceps, separate the connective tissue under the spleen with ophthalmic scissors, remove the spleen, and soak it in clean PBS solution.

[0110] (2) Place the spleen in a 70-mesh sieve and grind it gently with a tissue grinder until there are no obvious red lumps.

[0111] (3) Rinse the sieve with 15 mL of PBS and transfer the rinse solution from the 50 mL centrifuge tube to a 15 mL centrifuge tube. Centrifuge at 1200 g for 5 min and discard the supernatant.

[0112] (4) Add 2 mL of 1× red blood cell lysis buffer to resuspend the cells. After lysis at room temperature for 3 min, immediately add 10 mL of PBS, centrifuge at 1200 g for 5 min, and discard the supernatant.

[0113] (5) After centrifugation, remove the centrifuge tube, discard the supernatant, wash twice with PBS, and resuspend in 1640 culture medium.

[0114] (6) Adjust the cell concentration to 10×10^6 cells / ml using 1640 culture medium.

[0115] (7) Cell staining.

[0116] Treg staining steps: 1) The model group was set up as a negative control tube, CD4+ single staining tube, CD25+ single staining tube, Fox P3+ single staining tube and triple staining tube, and the other groups were set up as triple staining tubes. Take 100μl of cell suspension from each tube and add it to the EP tube. Add appropriate amount of antibodies, FITC Rat Anti-Mouse CD4 (4μl), PE-Cy™7 Rat Anti-Mouse CD25 (5μl) to mark surface molecules, and mix well. Incubate at 4℃ in the dark for 30min.

[0117] 2) Take out, add 1 ml of cold staining buffer to each tube, centrifuge at 2500 rpm, 4°C for 5 min; 3) Remove the supernatant, add 0.5 ml of freshly prepared Fix / Perm working solution to fix and permeabilize the membrane, and incubate at 4°C in the dark for 45 min; 4) Take out, add 0.5 ml Perm / Wash working solution, centrifuge at 2500 rpm, 4°C for 5 min; 5) Discard the supernatant, add 1 ml of Perm / Wash working solution, and centrifuge at 2500 rpm and 4°C for 5 min; 6) Discard the supernatant, add 100 μl Perm / Wash working solution, then add PE Rat Anti-Mouse Fox P3 (2 μl), and incubate at 4°C in the dark for 45 min; 7) Take out, add 1 ml of Perm / Wash working solution, centrifuge at 2500 rpm, 4°C for 5 min; 8) Discard the supernatant, add 1 ml of Perm / Wash working solution, and centrifuge at 2500 rpm and 4°C for 5 min; 9) Add 350 μl cold staining buffer to resuspend, store in 4°C refrigerator, detect by flow cytometry within 48 hours and analyze the data with Cyt Expert software.

[0118] Th17 staining steps: 1) Take 100 μl of cell suspension from each group, add it to EP tubes, and add FITC Rat Anti-Mouse CD4 (4 μl) to label surface molecules. Incubate at 4°C in the dark for 30 min; 2) Take out, add 1 ml cold stain buffer to each tube, centrifuge at 2500 rpm, 4°C for 5 min; 3) Remove the supernatant, add 0.5 ml of freshly prepared Fix / Perm working solution to fix and permeabilize the membrane, mix well, and incubate at 4°C in the dark for 45 min; 4) Take out, add 0.5ml Perm / Wash working solution to break the membrane and wash, centrifuge at 2500rpm, 4℃ for 5min; 5) Discard the supernatant, add 1 ml of Perm / Wash working solution, and centrifuge at 2500 rpm and 4°C for 5 min; 6) Discard the supernatant, add 100 μl Perm / Wash working solution, then add Alexa Fluor®647 Rat Anti-Mouse IL-17A (2 μl), and incubate at 4°C in the dark for 45 min; 7) Take out, add 1 ml of Perm / Wash working solution, centrifuge at 2500 rpm, 4°C for 5 min; 8) Discard the supernatant, add 1 ml of Perm / Wash working solution, and centrifuge at 2500 rpm and 4°C for 5 min; 9) Add 350 μl cold stain buffer to resuspend, store in 4°C refrigerator, and detect by flow cytometry within 48 hours and analyze with Cyt Expert software.

[0119] 3.2 ELISA In SLE patients, the presence of a large number of antinuclear antibodies in the serum is the most important pathological feature. Anti-dsDNA antibodies can be detected in about 75% of SLE patients, so they have high specificity and can be used as an indicator for active SLE.

[0120] Detection indicators: antinuclear antibodies (ANA), anti-dsDNA antibodies.

[0121] The ANA detection kit was purchased from Ruixin Biotechnology (RX202808M), and the anti-dsDNA antibody kit was purchased from ELISA (MM-46273M1).

[0122] 3.3 Kidney 3.3.1 Immunization a. Immunofluorescence Immune complex deposition is a necessary condition for lupus nephritis, and the interaction between immune complexes and the complement system is one of the key links in lupus nephritis. In most cases, lupus nephritis is caused by glomerular IgG and complement deposition. Complement C3 is a central component of the complement system and an important immune molecule involved in the inherent immunity of lupus nephritis, with high specificity. Immunofluorescence can be used to assess the degree of immune damage in lupus nephritis.

[0123] Detection indicators: IgG, C3.

[0124] Immunofluorescence detection of IgG and C3 steps: (1) Dewaxing of paraffin sections: Place the sections in environmentally friendly dewaxing solution I for 10 min, environmentally friendly dewaxing solution II for 10 min, environmentally friendly dewaxing solution III for 10 min, anhydrous ethanol I for 5 min, anhydrous ethanol II for 5 min, anhydrous ethanol III for 5 min, and then wash with distilled water.

[0125] (2) Antigen repair: EDTA 8.0 repair solution, medium heat for 9 minutes, stop heating for 7 minutes, and switch to medium-low heat for 7 minutes. During the repair process, excessive evaporation of the buffer should be prevented and the slides should not be dried. After the repair is completed, cool naturally. Place the slides in PBS (PH7.4) and shake on a decolorizing shaker to wash 3 times, 5 minutes each time.

[0126] (3) Circle serum blocking: After the slices are slightly dried, use a histochemical pen to draw a circle around the tissue, add BSA (if the primary antibody is from goat, use 10% donkey serum to block, and if the primary antibody is from other sources, use 3% BSA to block), and block for 30 minutes.

[0127] (4) Add primary antibody: Add the prepared primary antibody (C3, Abcam, Ab200999; IgG, Sewell, GB25301) dropwise, and place the slices flat in a humidified box and incubate overnight at 4°C.

[0128] (5) Add secondary antibody: Place the slide in PBS (pH 7.4) and wash on a decolorizing shaker three times, 5 minutes each time. Add the corresponding secondary antibody and incubate at room temperature in the dark for 50 minutes.

[0129] (6) DAPI counterstaining of cell nuclei: Place the slide in PBS (pH 7.4) and wash on a decolorizing shaker three times, 5 minutes each time. Add DAPI staining solution and incubate at room temperature for 10 minutes in the dark.

[0130] (7) Quenching tissue autofluorescence: Place the slide in PBS (PH7.4) and wash on a decolorizing shaker three times, 5 minutes each time. Add autofluorescence quencher B solution for 5 minutes and rinse with running water for 10 minutes. (If you need to observe tissue autofluorescence, then remove this step).

[0131] (8) Sealing: Use anti-fluorescence fading sealing medium to seal the slices.

[0132] (9) Collect images.

[0133] b. Western Blot / Immunohistochemistry Complement C3 signaling pathway validation: After the antigen binds to the antibody, C1q can recognize and bind to the complement binding site on the antibody, activating C1r and C1s in turn; C1s cleaves C4 and C2 in turn to form C4b2a (C3 convertase) with enzymatic activity. C3 is cleaved by C4b2a into two fragments, C3a and C3b. C3b combines with C4b2a to produce C4b2a3b, which is the C5 convertase of the classical pathway. C5 is cleaved into C5a and C5b under the action of C4b2a3b. There is evidence that C3a and C5a are powerful chemical inducers that can induce neutrophils, monocytes and macrophages to complement activation sites by binding to their receptors, thereby promoting inflammation. Experiments have been conducted to verify whether Lactobacillus rhamnosus can reduce the release of inflammatory factors by reducing related proteins in the classical complement activation pathway.

[0134] Detection indicators: C3, C5.

[0135] WB detection steps for C3 and C5: Ⅰ Preparation of protein samples: ①Take out the tissue sample from the -80℃ freezer and cut off about 0.1 g of tissue with surgical scissors (keep it on ice throughout the process); ②Put 0.1 g of tissue in a 10 mL centrifuge tube and chop it with scissors. It can be temporarily stored in a 4℃ or -20℃ refrigerator; ③ Add the prepared lysis buffer to a 10 mL centrifuge tube. Add 1 mL of lysis buffer to each sample, including 800 μL of RIPA, 100 μL of PMSF, and 100 μL of phosphatase inhibitor (1 mL of lysis buffer is used for every 50-100 mg of tissue); ④Use a homogenizer to homogenize, keep it on ice throughout the process, clean the drill bit before and after homogenization, wipe it gently with toilet paper, and there is no fixed homogenization time until there are no obvious tissue blocks in the tube; ⑤Stand on ice until there is no obvious foam, transfer it to a 1.5 mL EP tube, shake for 15 seconds, stand for 15 minutes, repeat this operation 3 times, pre-cool in a 4℃ centrifuge, and centrifuge at 12,000 rpm for 10 minutes; ⑥Pipette the supernatant into a new EP tube and store it in a -80℃ refrigerator. The supernatant is the whole protein (there may be white connective tissue and fat in the supernatant, do not pipette it, just take the middle layer); ⑦ Take 200 μL of the supernatant and add 50 μL of 5× loading buffer, then boil it in a water bath at 100℃ for 10 min. After boiling, place it in a -20℃ refrigerator and it can be used for WB.

[0136] Ⅱ BCA assay: ① Divide the 96-well plate into areas; ② Prepare BSA protein standard sample: dilute 2 mg / mL protein standard solution to 0.5 mg / mL (if 200 µL of 0.5 mg / mL protein standard solution is prepared, 50 µL of 2 mg / mL protein standard solution and 150 µL of PBS solution are required); ③ Prepare BCA working solution: Mix BCA reagent A and B at a ratio of 50:1 (2450 µL A + 49 µL B) to make an appropriate amount of BCA working solution; ④ Dilute BSA protein standard: add 0, 1, 2, 4, 8, 12, 16, 20 µL of standard sample to the labeled area, then fill the wells with PBS to 20 µL, and add 200 µL of BCA to each well; ⑤ Dilute the protein sample to be tested: dilute to 20 µL with PBS (the sample must be diluted to a certain multiple for quantification, 2 µL sample + 18 µL PBS, i.e. 10-fold dilution), and then add 200 µL BCA to each well; ⑥ Incubate the added 96-well plate at 37°C for 30 minutes; ⑦ After incubation, place the sample in a microplate reader and shake it gently for 3-10 seconds at a medium speed with an absorbance of 595 nm for colorimetric determination. After recording the standard curve and sample absorbance data, a standard curve is drawn with protein content (mL) as the horizontal axis and absorbance as the vertical axis. (R2>0.98); ⑧Calculate the protein content.

[0137] Protein quantification standard curve loading amount: Serial number 12345678; Standard protein amount / µL (0.5 mg / mL) 01248121620; Background solution (PBS) / µL2019181612840; Standard solution concentration mg / mL00.0250.050.10.20.30.40.5; Ⅲ Prepare separation gel and stacking gel: (separation gel: 7.5 mL, stacking gel: 2 mL) The concentration of separation gel depends on the size of the protein to be separated. Generally, separation gel with high concentration is used to separate small molecular proteins, and separation gel with low concentration is used to separate large molecular proteins; IV. Preparation of polyacrylamide gel: After leak detection, add 7.5 mL of separation gel to the gel plate, then add a certain volume (about 200 uL) of isopropanol (to drive away bubbles and flatten the separation gel). After the separation gel solidifies, pour out the isopropanol, wash with deionized water, dry with absorbent paper, add 2 mL of concentrated gel, slowly put the comb into the concentrated gel from right to left to prevent bubbles, and let it stand for a while until the gel solidifies; V. Sample loading: After the colloid solidifies, carefully remove the comb and add a certain amount of the sample to be tested into the sample well. After the sample loading is completed, add 2 µL of marker; Ⅵ Electrophoresis: Run the gel in SDS running buffer at 80 V for 30 min, then at 120 V for 1 h (the electrophoresis buffer can be recovered after the run); Ⅶ Transfer: Transfer the protein from the gel to the nitrocellulose membrane, and keep the gel with the required band for transfer. There are two specifications of NC membrane, 0.22 µm is suitable for proteins of 15-20 bp in size, and 0.45 µm is suitable for proteins of 70-100 bp in size. The membrane needs to be soaked in methanol in advance. Place the gel on a splint in a plate filled with transfer fluid, making sure that the transfer fluid soaks the gel, and then cover it with the soaked NC membrane, taking care not to generate bubbles. Then place the splint (sandwich) in the transfer tank for transfer (ice bath). The transfer time for small molecules is generally 90 mA, 90 min, and the transfer time for large molecules is generally 260 mA, 50 min; VIII Blocking: After the transfer, place the splint in a plate, take out the NC membrane, and block it in 5% skim milk for 1 h; Ⅸ Primary antibody incubation: Add diluted primary antibody to the membrane and shake overnight at 4°C; (recover primary antibody); Ⅹ Washing: Wash the membrane three times with 0.2% PBST, 10 minutes each time; ⅩⅠ Secondary antibody incubation: add goat anti-mouse immunoglobulin-horseradish peroxidase (HRP) labeled secondary antibody and incubate at room temperature for 1 h; ⅩⅡ Washing: Wash the membrane three times with 0.2% PBST, 10 minutes each time; ⅩⅢ Place the membrane in a sealed bag and add freshly prepared chemiluminescent reagent for development.

[0138] 3.3.2 Inflammation a. HE staining (histological changes, pathological changes) Purpose of detection: To observe the pathological changes in the kidneys of experimental mice, including the structure, size, and nuclear-cytoplasmic ratio of cells.

[0139] (Typical pathological changes of lupus nephritis: moderate to severe increase in mesangial cells, significant widening of the mesangial matrix, segmental sclerosis of the glomeruli, proliferation of capillary endothelial cells, and obvious stenosis of the luminal cavity.) HE staining steps: (1) Sampling and fixation: Melanoma tumor tissues were obtained from mice by dissection and fixed in a 4% paraformaldehyde fixative. (2) Dehydration: The fixed melanoma tumor tissue was removed, rinsed thoroughly with PBS, and then dehydrated with ethanol. Dehydrated with 70% ethanol, 80% ethanol, 90% ethanol, 95% ethanol I, 95% ethanol II, 100% ethanol I, and 100% ethanol II for 1 h in sequence; (3) Embedding: The dehydrated tissue was treated with xylene for 30 min and then embedded in paraffin. (4) Sectioning and sealing: Use a rotary machine to cut a flat surface, set the section thickness to 3-5 μM, carefully pick up the cut wax slice, place it in the water tank of a slide spreader at 45°C, and flatten the wrinkled wax slice; place the wax slice on a glass slide, place it on a 60°C slide baking machine, and bake it for 4 h; (5) Dewaxing: Place the tissue sample slices to be tested in xylene and soak them for 10 min. After soaking, replace the xylene and continue soaking for 10 min. (6) Hydration: Soak the tissue sample that has been soaked in xylene in anhydrous ethanol for 5 min to allow the xylene used in dewaxing to be washed out and water to enter the tissue; then soak it in 100%, 90%, 80%, and 70% ethanol for 5 min each to achieve full hydration; (7) Hematoxylin staining, differentiation and anti-blueing of tissue sections: Soak the sections of the hydrated tissue samples in PBS solution for 5 minutes each time, and wash them 3 times in total. Then use a pipette to draw up the pre-prepared hematoxylin staining solution, add 100μl to each tissue section, and stain it for 10 minutes. After staining, use distilled water to wash away the excess hematoxylin staining solution. Then use 1% hydrochloric acid ethanol for differentiation to remove excess dye in the cell nucleus and excess dye in the cytoplasm. After differentiation is completed, rinse the tissue sections with double distilled water. In order to make hematoxylin stain blue, use a weakly alkaline blueing solution to add to the tissue sections to stain the cell nucleus blue. After the anti-blueing is completed, first wash with clean water, and then rinse the tissue sections with double distilled water; (8) Eosin staining and dehydration of tissue sections: Add eosin staining solution to the tissue sample sections from the previous step and allow the tissue to be fully stained for 3 minutes. After staining, the tissue sections are dehydrated in a gradient manner using 80%, 95%, and anhydrous ethanol, respectively. Dehydrate with 80% ethanol for 5 seconds, 95% ethanol for 2 minutes, and anhydrous ethanol for 2 minutes. (9) Sealing: Soak the dehydrated tissue sample slices in xylene twice, each time for 4 minutes, then slice the tissue sample and seal the slices with neutral gum; (10) Observation: Place the coverslip under an optical microscope, take photos, and perform pathophysiological analysis.

[0140] b. qPCR detection of cytokines The expression levels of typical inflammatory factors in the kidney were detected by Western blotting experiments to evaluate the alleviating effect of Lactobacillus rhamnosus on lupus nephritis.

[0141] Detection indicators: IL-1β, IL-6, IFN-α.

[0142] qPCR detection steps for IL-1β, IL-6, and IFN-α: Ⅰ Extraction of RNA from tissues (1) Weigh 50-100 mg of tissue, chop it thoroughly, add 1 mL of Trizol solution and grind it with a homogenizer to lyse the cells. Note that the total volume of the sample should not exceed 10% of the volume of Trizol used. Then place it at room temperature (15-30°C) for 5 minutes. (2) Add 0.2 mL of chloroform to every 1 mL of Trizol solution, cover the centrifuge tube tightly, shake vigorously on a vortex shaker for 15 seconds, and leave at room temperature for 2-3 minutes; (3) Centrifuge at 12,000 rpm, 4°C for 15 min; (4) Transfer the top aqueous phase to a new centrifuge tube (second Eppendorf tube), add 0.5 mL of isopropanol per 1 mL of Trizol solution, and leave at room temperature for 10 min. (5) Centrifuge at 12,000 rpm, 4°C for 15 min; (6) Discard the supernatant, add 1 mL of 75% ethanol (prepared with DEPC water) per mL of Trizol solution for washing, vortex to mix, centrifuge at 12,000 rpm, 4°C for 15 min, and repeat twice; (7) Discard the supernatant and allow the precipitated RNA to dry naturally at room temperature for 5-10 min. (8) Add an appropriate amount of RNase-free water to dissolve the RNA precipitate and mix it repeatedly with a pipette tip; (9) Incubate in a 65°C water bath for 15 min and store at -80°C until use; (10) The RNA concentration and purity were determined by UV absorption method (NanoDrop 2000 spectrophotometer).

[0143] Reverse transcription to cDNA, reverse transcription of RNA using TAKARA reverse transcription kit: (1) Removal of genomic DNA Prepare the reaction mixture on ice according to the following ingredients. To ensure the accuracy of the reaction mixture preparation, when performing each reaction, prepare the Master Mix according to the amount of reaction number + 2, then dispense it into each reaction tube, and finally add the RNA sample.

[0144]

[0145] In a water bath at 42°C for 2 min.

[0146] (2) Reverse transcription reaction All steps were performed on ice. For each reaction, prepare the Master Mix according to the number of reactions + 2, and then dispense 10 uL into each reaction tube. After gentle mixing, immediately proceed with the reverse transcription reaction.

[0147]

[0148] All the above steps were performed on ice, and the reaction conditions were 37°C for 15 min and then 85°C for 5 s.

[0149] (3) Real Time PCR

[0150] (4) PCR conditions Stage 1: 95 °C, 30 s; Stage 2: (95 °C, 5 s; 60 °C, 34 s) 40 cycles; The third stage: 95 ℃, 15 s; 60 ℃, 1 min; 95 ℃, 15 s.

[0151] (5) PCR results: Confirm the amplification curve and melting curve of Real Time PCR and create a standard curve when performing PCR quantification.

[0152] c. Western blot experiment to verify TLR9 / MyD88 / NF-κB pathway Studies have shown that the genes of B lymphocytes in SLE patients are in a state of hypomethylation. Toll-like receptor 9 (TLR9) is a transmembrane protein that can recognize hypomethylated DNA. When TLR9 binds to the ligand, myeloid differentiation factor 88 (MyD88) is released and aggregates and binds to the TIR domain at the free carboxyl end of TLR9. Activated MyD88 phosphorylates and degrades NF-κB inhibitory protein (IκB) through the NF-κB inhibitory protein kinase (IKK) signal cascade. Ultimately, the nuclear localization signal of MyD88 is exposed, prompting NF-κB to migrate into the nucleus and activate the transcription of the corresponding gene.

[0153] Detection indicators: TLR9, MyD88, NF-κB, p-NF-κB.

[0154] WB detection steps of TLR9, MyD88, NF-κB, and p-NF-κB: Ⅰ Preparation of protein samples: ①Take out the tissue sample from the -80℃ freezer and cut off about 0.1 g of tissue with surgical scissors (keep it on ice throughout the process); ②Put 0.1 g of tissue in a 10 mL centrifuge tube and chop it with scissors. It can be temporarily stored in a 4℃ or -20℃ refrigerator; ③ Add the prepared lysis buffer to a 10 mL centrifuge tube. Add 1 mL of lysis buffer to each sample, including 800 μL of RIPA, 100 μL of PMSF, and 100 μL of phosphatase inhibitor (1 mL of lysis buffer is used for every 50-100 mg of tissue); ④Use a homogenizer to homogenize, keep it on ice throughout the process, clean the drill bit before and after homogenization, wipe it gently with toilet paper, and there is no fixed homogenization time until there are no obvious tissue blocks in the tube; ⑤Stand on ice until there is no obvious foam, transfer it to a 1.5 mL EP tube, shake for 15 seconds, stand for 15 minutes, repeat this operation 3 times, pre-cool in a 4℃ centrifuge, and centrifuge at 12,000 rpm for 10 minutes; ⑥Pipette the supernatant into a new EP tube and store it in a -80℃ refrigerator. The supernatant is the whole protein (there may be white connective tissue and fat in the supernatant, do not pipette it, just take the middle layer); ⑦ Take 200 μL of the supernatant and add 50 μL of 5× buffer, then place it in a water bath and boil it at 100℃ for 10 min. After it is cooked, place it in a -20℃ refrigerator and it can be used for WB.

[0155] Ⅱ BCA assay: ① Divide the 96-well plate into areas; ② Prepare BSA protein standard sample: dilute 2 mg / mL protein standard solution to 0.5 mg / mL (if 200 µL of 0.5 mg / mL protein standard solution is prepared, 50 µL of 2 mg / mL protein standard solution and 150 µL of PBS solution are required); ③ Prepare BCA working solution: Mix BCA reagent A and B at a ratio of 50:1 (2450 µL A + 49 µL B) to make an appropriate amount of BCA working solution; ④ Dilute BSA protein standard: add 0, 1, 2, 4, 8, 12, 16, 20 µL of standard sample to the labeled area, then fill the wells with PBS to 20 µL, and add 200 µL of BCA to each well; ⑤ Dilute the protein sample to be tested: dilute to 20 µL with PBS (the sample must be diluted to a certain multiple for quantification, 2 µL sample + 18 µL PBS, i.e. 10-fold dilution), and then add 200 µL BCA to each well; ⑥ Incubate the added 96-well plate at 37°C for 30 minutes; ⑦ After incubation, place the sample in a microplate reader and shake it gently for 3-10 seconds at a medium speed with an absorbance of 595 nm for colorimetric determination. After recording the standard curve and sample absorbance data, a standard curve is drawn with protein content (mL) as the horizontal axis and absorbance as the vertical axis. (R2>0.98); ⑧Calculate protein content: Protein quantification standard curve loading amount: Serial number 12345678 Standard protein volume / µL (0.5 mg / mL) 01248121620 Background solution (PBS) / µL2019181612840 Standard solution concentration mg / mL00.0250.050.10.20.30.40.5.

[0156] Ⅲ Prepare separation gel and stacking gel: (separation gel: 7.5 mL, stacking gel: 2 mL) The concentration of separation gel depends on the size of the protein to be separated. Generally, separation gel with high concentration is used to separate small molecular proteins, and separation gel with low concentration is used to separate large molecular proteins; IV. Preparation of polyacrylamide gel: After leak detection, add 7.5 mL of separation gel to the gel plate, then add a certain volume (about 200 uL) of isopropanol, pour out the isopropanol after the separation gel solidifies, wash with deionized water, dry with absorbent paper, then add 2 mL of concentrated gel, slowly put the comb into the concentrated gel from right to left to prevent bubbles, and let it stand for a while until the gel solidifies; V. Sample loading: After the colloid solidifies, carefully remove the comb and add a certain amount of the sample to be tested into the sample well. After the sample loading is completed, add 2 µL of marker; VI. Electrophoresis: Run the gel in SDS running buffer at 80 V for 30 min, followed by 120 V for 1 h. Ⅶ Transfer: Transfer the protein from the gel to the nitrocellulose membrane, and keep the gel with the required band for transfer. There are two specifications of NC membrane, 0.22 µm is suitable for proteins of 15-20 bp in size, and 0.45 µm is suitable for proteins of 70-100 bp in size. The membrane needs to be soaked in methanol in advance. Place the gel on a splint in a plate filled with transfer fluid, making sure that the transfer fluid soaks the gel, and then cover it with the soaked NC membrane, taking care not to generate bubbles. Then place the splint (sandwich) in the transfer tank for transfer (ice bath). The transfer time for small molecules is generally 90 mA, 90 min, and the transfer time for large molecules is generally 260 mA, 50 min; VIII Blocking: After the transfer, place the splint in a plate, take out the NC membrane, and block it in 5% skim milk for 1 h; Ⅸ Primary antibody incubation: Add diluted primary antibody to the membrane and shake overnight at 4°C; Ⅹ Washing: Wash the membrane three times with 0.2% PBST, 10 minutes each time; ⅩⅠ Secondary antibody incubation: add goat anti-mouse immunoglobulin-horseradish peroxidase (HRP) labeled secondary antibody and incubate at room temperature for 1 h; ⅩⅡ Washing: Wash the membrane three times with 0.2% PBST, 10 minutes each time; ⅩⅢ Place the membrane in a sealed bag and add freshly prepared chemiluminescent reagent for development.

[0157] 3.4.1 Intestine 3.4.1.1 High-throughput sequencing Fecal samples were collected from the intestine for high-throughput sequencing (sampling at different stages of the disease can better understand the dynamic regulation of the intestinal environment and metabolic function by probiotics, and attention should be paid to sampling at multiple time points). 16S ribosomal DNA gene sequencing was used to identify and divide bacterial groups, compare the differences in intestinal flora between the systemic lupus erythematosus model group and the treatment group, and explore the value of Lactobacillus rhamnosus in the pathogenesis, diagnosis, and treatment of lupus.

[0158] Steps for high-throughput sequencing to detect intestinal flora: Total genomic DNA from mouse fecal samples was extracted using a bacterial genome extraction kit (QIAGEN) as instructed. The concentration and quality of the extracted genomic DNA were assessed by spectrophotometer (Thermo Fisher Scientific, USA). The extracted DNA was subjected to 16S sequencing at Shanghai Paisono Biotechnology Co., Ltd. The PCR amplification products were sequenced using the Illumina MiSeq platform. FLASH was used to merge overlapping reads, and the UPARSE software package was used for sequence analysis. Reads with a quality score lower than 20, ambiguous bases, and inappropriate primers were discarded before clustering, and chimeras were checked and eliminated during the clustering process. ASV / OTU signature sequences were obtained using the DADA2 method and then processed using Quantitative Insights into MicrobialEcology (QIIME). The relative abundance of the total bacteria in each sample was classified into different taxonomic levels (phylum, class, order, family, and genus) using the Greengenes database v13.8 (19).

[0159] 3.4.1.2 Western blotting a. Intestinal permeability test Studies have shown that the imbalance of intestinal flora in SLE patients affects the intestinal mucosal barrier function, leading to immune dysfunction, which may be closely related to the occurrence and development of SLE diseases and complications such as kidney damage. Taking Lactobacillus rhamnosus is used to explore whether it can improve intestinal permeability, further improve SLE immunity, and reduce complications.

[0160] The colon was taken for photographing, and the intestinal epithelial cells were isolated and the levels of tight junction proteins, including ZO-1, transmembrane proteins Ocludin and Claudin-1, were measured by WB experiments. The experimental method was the same as that in part (c) of 3.3.2 above.

[0161] b Verification of intestinal TLR4 / MyD88 signaling pathway In SLE mice, the intestinal bacterial product LPS enters the body through the intestinal barrier and combines with the LPS binding protein (LPB) in the blood to form a complex, which interacts with molecules on the surface of monocytes / macrophages to further form an LPS-LPB complex, transmits the signal into the cell, and then activates TLR4 through the MD-2 protein. TLR4 further transmits the signal downward through downstream molecules such as TRAF and IRAK in the cell, ultimately activating the NF-κB and MAPK pathways, leading to the expression of a large number of pro-inflammatory factors.

[0162] Experiments have shown that probiotics can inhibit the inflammatory immune response to pathogen invasion by inhibiting the expression of TLR4, which recognizes pathogens. Western blot experiments were used to detect key proteins in the TLR4 / MyD88 signaling pathway in peripheral blood to see whether Lactobacillus rhamnosus can improve the intestinal barrier and improve immunity by inhibiting this pathway.

[0163] Detection indicators: TLR4, MyD88, IκB, p-IκB, NF-κB, p-NF-κB.

[0164] 3.4.1.3 qPCR experiments c. Detection of intestinal inflammation level The expression levels of typical inflammatory factors in the intestine were detected by Western blotting experiments to evaluate the alleviating effect of Lactobacillus rhamnosus on enteritis.

[0165] Detection indicators: IL-1β, IL-6, TNF-α. The experimental method is the same as part (b) in 3.3.2 above.

[0166] 4 Experimental Results 4.1 Cultivation of LC-STH-13 and evaluation of its probiotic properties in vitro In order to evaluate the growth performance of the probiotic strain, the present invention plotted its growth curve by detecting the OD600nm of LC-STH-13. Figure 1 As shown in A, LC-STH-13 entered the logarithmic growth phase after 4 h of culture and reached the stable phase after 12 h, indicating that its growth activity was vigorous ( Figure 1 A in the figure).

[0167] The present invention further studies the probiotic properties of LC-STH-13, including tolerance to gastric acid and intestinal bile salts, hemolytic activity, antioxidant capacity, and inhibition of the growth of common intestinal pathogens.

[0168] The results of the gastric acid tolerance test showed that LC-STH-13 exhibited optimal activity at pH=7, with a survival count of up to 10 9 CFU / mL; in addition, even under acidic conditions of pH=2, the viable count remains at 10 6High levels of CFU / mL ( Figure 1 B in Figure 1 In the bile salt tolerance test, LC-STH-13 showed good tolerance to bile salts. At a bile salt concentration of 0.3%, the viable bacterial count was 10 6 CFU / mL( Figure 1 D in.

[0169] The present invention further evaluated the antioxidant properties of the strain ( Figure 1 E). The scavenging rate of LC-STH-13 on DPPH, OH-, and ·O2 - The free radicals were 87.69%, 86.35% and 46.56% respectively. 2+ The chelation rate was 90.48% and the total reducing power was 1.946.

[0170] Probiotics can exert their probiotic properties by inhibiting the growth of pathogenic bacteria. In the antagonistic activity assay against pathogenic bacteria ( Figure 1 The inhibition zones of LC-STH-13 against Salmonella enterica ATCC 13311, Candida albicans SC531, Salmonella enteritidis ATCC13076, Streptococcus β-hemolyticus, Escherichia coli O157:H7, Shigella flexneri ATCC 12022, Shigella dysenteriae 301, and Staphylococcus aureus 13311 were 22.0 mm, 22.0 mm, 22.0 mm, 21.7 mm, 21.3 mm, 20.0 mm, 19.3 mm, 20.7 mm, and 20.7 mm, respectively. These results indicate that LC-STH-13 has good probiotic properties.

[0171] Probiotics can exert their probiotic effects by adhering to intestinal epithelial cells. LC-STH-13 was co-incubated with human colon cancer cells HT-29, and the results showed that LC-STH-13 can adhere to colon epithelial cells without destroying the cell morphology ( Figure 1 in G).

[0172] In the hemolytic activity test, no hemolytic zone similar to that of Staphylococcus aureus was observed around the colonies of lactic acid bacteria LC-STH-13, indicating that it had no hemolytic activity ( Figure 1 in H).

[0173] The results of drug sensitivity test showed that LC-STH-13 was sensitive to ampicillin (AMP), penicillin (PEN), erythromycin (E), tetracycline (TET), cephalosporin (C) ( Figure 1 I in the text box).

[0174] 4.2 Effects of LC-STH-13 on systemic lupus erythematosus and intestinal flora 4.2.1 LC-STH-13 alleviates lupus in MRL / lpr mice The present invention uses systemic lupus erythematosus (SLE) model mice-MRL / lpr female mice, which are gavaged with gelatin saline, prednisolone, low dose (10 7 CFU) and high doses (10 9 CFU) of LC-STH-13, and C57BL / 6 mice served as the control group ( Figure 2 ), to explore the effect of LC-STH-13 on systemic lupus erythematosus.

[0175] The results showed that the weight gain of mice in the high-dose LC-STH-13 group (H-LC group) was more significant than that in the prednisolone-treated group (Pred group). Figure 3 A in the figure). SLE is a chronic autoimmune disease characterized by excessive production of anti-autoantibodies. Antinuclear antibodies (ANA) and anti-double-stranded DNA (ds-DNA) antibodies are the most sensitive and specific anti-autoantibodies in SLE, respectively. ELISA tests showed that the concentrations of ANA and ds-DNA antibodies in the serum of mice in the H-LC group were significantly lower than those in the M group ( Figure 3 B in Figure 3 C in.

[0176] In addition, spleen enlargement was commonly observed in MRL / lpr mice, and oral administration of LC-STH-13 significantly alleviated this symptom ( Figure 4 A in Figure 4 In view of the fact that the progression of systemic lupus erythematosus is closely related to helper T lymphocytes, the present invention evaluated the relative levels of Th17 and Treg cells in the spleen of mice. The results showed that LC-STH-13 can effectively alleviate the imbalance of helper T lymphocytes in MRL / lpr mice ( Figure 5-Figure 6 , Figure 7 A in Figure 7 The above results indicate that high doses of LC-STH-13 can improve lupus progression in MRL / lpr mice by reducing the production of circulating anti-autoantibodies and alleviating the imbalance of Th17 and Treg cells.

[0177] 4.2.2 LC-STH-13 improves renal injury in MRL / lpr mice Lupus nephritis (LN) is a common organ damage in SLE, characterized by immune complex glomerulonephritis. Serum creatinine and blood urea nitrogen are closely related to glomerular filtration function. By detecting their expression, it was found that high-dose LC-STH-13 (H-LC group) and glucocorticoids (Pred group) had similar effects and could reverse the renal function damage caused by nephritis ( Figure 8 A in Figure 8 B in the figure). Further HE staining of mouse kidney sections showed obvious inflammatory cell infiltration in the kidney tissue of MRL / lpr mice (group M). Compared with the M group, the kidney tissue of the H-LC group was significantly improved, with significantly reduced interstitial hyperplasia and inflammatory cell infiltration ( Fig. 9 In addition, the immunofluorescence results of IgG and C3 in the kidney also showed that high doses (10 9 CFU) LC-STH-13 can reduce the deposition of immune complexes and complement in the glomeruli caused by lupus ( Fig.10 , Fig.11 ).

[0178] 4.2.3 LC-STH-13 reduces renal immune complex deposition and inflammation in MRL / lpr mice The deposition of circulating immune complexes and in situ complexes in the kidney can activate complement C3 and C5, and ultimately mediate cytotoxicity through the attack membrane complex. The expression of complement C3 and complement C5 in the kidney was detected by WB, and it was found that the relative expression of complement in the M group mice was significantly increased, revealing the overactivation of the complement system. Similar to the effect of the Pred group, the complement level of the H-LC group mice was significantly reduced compared with the M group, indicating that high doses (10 9 CFU) of LC-STH-13 can improve the excessive complement production caused by lupus ( Fig.12 AC in the ).

[0179] Previous studies have shown that TLR9 activation aggravates kidney damage by enhancing the deposition of DNA autoantibodies in the glomeruli. Therefore, we investigated whether the effect of Lactobacillus rhamnosus on kidney damage depends on the TLR9 / NF-кB signaling pathway. The expression of TLR9, MyD88, and p-NF-кB in the kidneys of mice in the M group was enhanced ( Fig.14 A, B, C), while high doses (10 9 CFU) of LC-STH-13 significantly reduced the expression of p-NF-κB ( Fig.14 In addition, the transcriptional levels of IFN-α, IL-1, and IL-6, the downstream inflammatory factors in the pathway, were also significantly reduced after LC-STH-13 intervention ( Fig.13 A in Fig.13 B in Fig.13 C). These data indicate that LC-STH-13 intervention can negatively regulate the TLR9 / NF-кB signaling pathway and alleviate renal injury in MRL / lpr mice.

[0180] 4.2.4 LC-STH-13 alleviates intestinal microbial disturbances in MRL / lpr mice The Chao 1 index, observed_species, and faith_pd index reflect the α diversity of the intestinal microbiota to evaluate the richness and uniformity of the intestinal microbial population. Compared with the mice in the C group, the α diversity of intestinal microorganisms in the M group mice was reduced, and the administration of LC-STH-13 could increase the α diversity of intestinal microorganisms in the MRL / lpr mice ( Fig.15 The PCoA score plot visualizes the β diversity of intestinal microorganisms, and there is a clear separation between mice in the M group and mice in the C group ( Fig.16 B in the figure).

[0181] The Venn diagram can be used to count the number of common and unique OTUs in the intestines of each group of mice through the overlap and difference between the groups. Fig.16 As shown in A, there were 1201 OUTs in the five groups, of which 189 OUTs were shared by all groups, 141 OUTs were unique to the M group, 202 OUTs were unique to the Pred group, 168 OUTs were unique to the L-LC group, and 242 OUTs were unique to the H-LC group. This indicates that Lactobacillus rhamnosus treatment can effectively increase the OUTs of MRL / lpr mice and alleviate the reduction of OUTs caused by prednisolone treatment.

[0182] To further explore the role of Lactobacillus rhamnosus in regulating intestinal microbes, we analyzed the changes between the phylum and genus levels among the groups. Bacteroidetes and Firmicutes accounted for more than 90% of the total richness and were the main phyla in the mouse intestinal microbes ( Fig.17 In the intestine of group M mice, the abundance of Bacteroidetes increased, and supplementation with LC-STH-13 reversed this change in a dose-dependent manner ( Fig.17 In contrast, Firmicutes and Proteobacteria showed the opposite trend ( Fig.17 C in ). At the genus level ( Fig.18 A in the figure), the abundance of Lactobacillus in the M group mice was reduced, and supplementation of LC-STH-13 could significantly increase the abundance of Lactobacillus in the intestines of MRL / lpr mice ( Fig.18 B in the figure).

[0183] 4.2.5 LC-STH-13 reduces intestinal barrier damage and inflammation in MRL / lpr mice The intestinal barrier can prevent bacteria, toxins and other harmful substances from entering the body through the intestinal wall. Literature has shown that the development of SLE is not only related to the reduction of intestinal microbial diversity, but also closely related to the damage of the intestinal barrier. In order to study whether LC-STH-13 can alleviate the damage of the intestinal barrier caused by SLE, we performed HE staining on the mouse colon. Fig.19 As shown, the intestines of mice in group M showed intestinal barrier damage, including crypt deformation and a large number of inflammatory cell infiltration, while high doses of LC-STH-13 could alleviate intestinal damage to a certain extent. Intestinal tight junction proteins are related to intestinal permeability. By detecting intestinal epithelial tight junction proteins ZO-1, Occludin and Claudin1 by WB, we found that LC-STH-13 could alleviate the decreased intestinal permeability caused by SLE in a dose-dependent manner ( Fig. 20 In addition, compared with the mice in group C, the levels of IL-1, IL-6, and TNF-α mRNA in the colon tissue samples of mice in group M were significantly increased, indicating that intestinal inflammation in MRL / lpr mice was increased, and LC-STH-13 was able to significantly alleviate the level of intestinal inflammation ( Fig.21 AD in). Through WB experiments to detect mouse colon tissue, we found that LC-STH-13 can inhibit the activation of TLR4 and reduce the phosphorylation expression of downstream NF-κB and IκB, thereby reducing the expression of inflammatory factors ( Fig.21 D in Fig. 22 in AD).

[0184] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions, improvements, etc. made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. The use of Lactobacillus rhamnosus in preparing a product for treating autoimmune diseases, characterized in that: The deposit number of the Lactobacillus rhamnosus is CGMCC No. 3994.

2. The use according to claim 1, characterized in that: The autoimmune disease is systemic lupus erythematosus.

3. The use according to claim 1, characterized in that: The viable count of Lactobacillus rhamnosus in the product is 1×10 3 -1×10 14 CFU / mL or 1×10 3 -1×10 14 CFU / g.

4. The use according to claim 3, characterized in that: The viable count of Lactobacillus rhamnosus in the product is 1×10 8 -1×10 10 CFU / mL or 1×10 8 -1×10 10 CFU / g.

5. The use according to claim 4, characterized in that: The viable count of Lactobacillus rhamnosus in the product is 1×10 10 CFU / mL or 1×10 10 CFU / g.

6. The use according to claim 1, characterized in that: The rhamnosus lactobacillus comprises fermentation liquid of rhamnosus lactobacillus, live rhamnosus lactobacillus and freeze-dried powder of rhamnosus lactobacillus.

7. The use according to claim 1, characterized in that: The product is a medicine, which includes a pharmaceutically acceptable carrier.

8. The use according to claim 7, characterized in that: The pharmaceutically acceptable carrier is selected from one or more of an excipient, a stabilizer, a diluent, a binder, a preservative, and a lubricant.

9. The use according to claim 7, characterized in that: The dosage form of the drug is drops, mixtures, tinctures, injections, tablets, powders, oral liquids, capsules, granules, ointments, suspensions, powders, emulsions, solutions, pellets, pills, buccal tablets, freeze-dried powder injections, gels, suppositories or aerosols.

10. A drug for treating autoimmune diseases, characterized in that: The medicine contains Lactobacillus rhamnosus, and the preservation number of the Lactobacillus rhamnosus is CGMCC No. 3994.

11. The drug according to claim 10, characterized in that The autoimmune disease is systemic lupus erythematosus.

12. The drug according to claim 10, characterized in that The viable count of Lactobacillus rhamnosus in the drug is 1×10 8 -1×10 10 CFU / mL or 1×10 8 -1×10 10 CFU / g.

13. The use of Lactobacillus rhamnosus in preparing a product for treating nephritis, characterized in that: The deposit number of the Lactobacillus rhamnosus is CGMCC No. 3994.

14. The use according to claim 13, characterized in that The nephritis is lupus nephritis.

15. The use according to claim 14, characterized in that: The product described is a pharmaceutical product.

Citation Information

Patent Citations

  • Lactobacillus rhamnosus, cultivation of lactobacillus rhamnosus and microcapsule method

    CN103031263A

  • Vesicles derived from lactobacillus rhamnosus and uses thereof

    CN117651560A

  • Composition for use in the prevention or treatment of inflammatory disease

    KR1020160053445A

  • Food container

    KR1020210112621A

Cited By

  • Lactobacillus rhamnosus strain A22004 with anti-inflammatory and anti-oxidation functions as well as derivative product and application of lactobacillus rhamnosus strain A22004

    CN119913063A